The industry must update its strategy for the digital age.
Shares rise following announcement.
Tissue engineering product previously flopped in EU.
Deloitte report makes grim reading for those in R&D.
J&J unit’s blockbuster gets new use.
Swiss pharma looking to combine immunotherapy with already marketed drugs.
Tailoring messages to the recipient’s needs results in a higher open rate and greater engagement.